» Articles » PMID: 27999568

Potential Antifungal Targets Against a Candida Biofilm Based on an Enzyme in the Arachidonic Acid Cascade-A Review

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2016 Dec 22
PMID 27999568
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Candida is an important opportunistic fungal pathogen, especially in biofilm associated infections. The formation of a Candida biofilm can decrease Candida sensitivity to antifungal drugs and cause drug resistance. Although many effective antifungal drugs are available, their applications are limited due to their high toxicity and cost. Seeking new antifungal agents that are effective against biofilm-associated infection is an urgent need. Many research efforts are underway, and some progress has been made in this field. It has been shown that the arachidonic acid cascade plays an important role in fungal morphogenesis and pathogenicity. Notably, prostaglandin E2 (PGE) can promote the formation of a Candida biofilm. Recently, the inhibition of PGE has received much attention. Studies have shown that cyclooxygenase (COX) inhibitors, such as aspirin, ibuprofen, and indomethacin, combined with fluconazole can significantly reduce Candida adhesion and biofilm development and increase fluconazole susceptibility; the MIC of fluconazole can be decrease from 64 to 2 μg/ml when used in combination with ibuprofen. In addition, studies have also confirmed the antifungal activities of these inhibitors. In this article, we mainly review the relationship between PGE and Candida biofilm, summarize the antifungal activities of COX inhibitors and analyze the possible antifungal activity of microsomal prostaglandin E synthase-1 (MPGES-1) inhibitors; additionally, other factors that influence PGE production are also discussed. Hopefully this review can disclose potential antifungal targets based on the arachidonic acid cascade and provide a prevailing strategy to alleviate biofilm formation.

Citing Articles

Exploring the anti-biofilm and gene regulatory effects of anti-inflammatory drugs on Candida albicans.

Yazdanpanah S, Shafiekhani M, Emami M, Khodadadi H, Pakshir K, Zomorodian K Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39731595 DOI: 10.1007/s00210-024-03727-y.


In Vitro Effect of Three-Antibiotic Combinations plus Potential Antibiofilm Agents against Biofilm-Producing and Clinical Isolates.

Batista S, Fernandez-Pittol M, Nicolas L, Martinez D, Rubio M, Garrigo M Antibiotics (Basel). 2023; 12(9).

PMID: 37760706 PMC: 10526108. DOI: 10.3390/antibiotics12091409.


Can nonsteroidal anti-inflammatory drugs (NSAIDs) be repurposed for fungal infection?.

Babaei F, Mirzababaei M, Tavakkoli A, Nassiri-Asl M, Hosseinzadeh H Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(1):59-75.

PMID: 37589736 DOI: 10.1007/s00210-023-02651-x.


Antimicrobial Efficiency of L. Derivates against Oral Biofilm-Associated Diseases-A Narrative Review.

Milia E, Sardellitti L, Eick S Microorganisms. 2023; 11(6).

PMID: 37374880 PMC: 10305426. DOI: 10.3390/microorganisms11061378.


Antimicrobial and Antibiofilm Effects of Combinatorial Treatment Formulations of Anti-Inflammatory Drugs-Common Antibiotics against Pathogenic Bacteria.

Tabatabaeifar F, Isaei E, Kalantar-Neyestanaki D, Morones-Ramirez J Pharmaceutics. 2023; 15(1).

PMID: 36678634 PMC: 9864814. DOI: 10.3390/pharmaceutics15010004.


References
1.
Ricardo E, Costa-de-Oliveira S, Dias A, Guerra J, Rodrigues A, Pina-Vaz C . Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes. FEMS Yeast Res. 2009; 9(4):618-25. DOI: 10.1111/j.1567-1364.2009.00504.x. View

2.
Peters-Golden M, Henderson Jr W . Leukotrienes. N Engl J Med. 2007; 357(18):1841-54. DOI: 10.1056/NEJMra071371. View

3.
Arai R, Sugita T, Nishikawa A . Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans. Mycoses. 2005; 48(1):38-41. DOI: 10.1111/j.1439-0507.2004.01052.x. View

4.
Bresalier R, Sandler R, Quan H, Bolognese J, Oxenius B, Horgan K . Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352(11):1092-102. DOI: 10.1056/NEJMoa050493. View

5.
Noverr M, Erb-Downward J, Huffnagle G . Production of eicosanoids and other oxylipins by pathogenic eukaryotic microbes. Clin Microbiol Rev. 2003; 16(3):517-33. PMC: 164223. DOI: 10.1128/CMR.16.3.517-533.2003. View